Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP-C1 in Metastatic Breast Cancer
NCT03603197Phase 2Completed
- Sponsor
- Meabco A/S
- Start
- Jun 2014
- Primary completion
- Aug 2016
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing BP-C1 Arm with Placebo Arm (2 arms). Primary endpoint: Change (%) in the sum of diameters of target lesions at Day 32. Started Jun 2014; status: completed.
02
Drugs
BP-C1
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03603197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603197.